#hepatitis C treatment

After inmates filed a class action lawsuit, Nevada agreed to treat all prisoners living with hepatitis C.

The risk was lower in people who had achieved a sustained virological response compared with those who had not.

Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.

Hepatitis A and E usually resolve on their own, but hepatitis B and C can cause serious liver disease, including cirrhosis and liver cancer.

Premature discontinuation of hepatitis C treatment did not diminish the likelihood of sustained virological response.

The hep C mortality reduction goal will not be met by any state, according to recent projections.

Researchers found that longer usage of injection drugs was positively linked to hep C testing.

Requiring sobriety prior to treatment and curtailing harm reduction hinder efforts to eliminate hep C.

The blood-borne virus, which can lead to cirrhosis and liver cancer, remains a major global health threat.

Some state Medicaid programs and prison systems still restrict treatment based on substance use or stage of liver disease.

A recent study of the direct-acting antiviral regimen included people who contracted hep C within the previous 12 months.

All people ages 18 to 79 should be screened for hepatitis C virus at least once, regardless of risk factors.

Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.

This is according to the largest-ever analysis of the treatment cascade among people tested for hepatitis C.

Preliminary results from an ongoing trial found that half of the participants could take less than 12 weeks of a cure regimen.

In the first five months of 2018, 803 HCV-positive organs were transplanted across the United States.